• Attar, E.C., Learner, E. & Amrein, P.C. (2004) In vitro studies of bortezomib with daunorubicin and cytarabine: sequence of administration affects leukemia cell chemosensitivity. Blood (ASH Annual Meeting Abstracts), 104, 4464.
  • Cella, D.F., Tulsky, D.S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S.B., Winicour, P. & Brannon, J. (1993) The functional assessment of cancer therapy (FACT) scale: development and validation of the general measure. Journal of Clinical Oncology, 11, 570579.
  • Cloos, J., Vink, J., Van Miltenburg, M., Oerlemans, R., Van Der Heijden, J., Dijkmans, B., Jansen, G. & Kaspers, G. (2004) Sensitization of leukemic cells for glucocorticoids by inhibition of NFKB activation. Blood (ASH Annual Meeting Abstracts), 104, 3395.
  • Fisher, R.I., Bernstein, S.H., Kahl, B.S., Djulbegovic, B., Robertson, M.J., De Vos, S., Epner, E., Krishnan, A., Leonard, J.P., Lonial, S., Stadtmauer, E.A., O’ Connor, O.A., Shi, H., Boral, A.L. & Goy, A. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology, 24, 48674874.
  • Gotoh, A., Ohyashiki, K., Oshimi, K., Usui, N., Hotta, T., Dan, K. & Ikeda, Y. (2006) Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the “lung injury by bortezomib” Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology. International Journal of Hematology, 84, 406412.
  • Goy, A., Remache, Y., Barkoh, B., Jiang, Y., Hart, S. & Gilles, F. (2004) Sensitivity, schedule-dependence and molecular effects of the proteasome inhibitor bortezomib in non-Hodgkin’s lymphoma cells. Blood (ASH Annual Meeting Abstracts), 104, 1387.
  • Herrmann, A., Hoster, E., Zwingers, T., Brittinger, G., Engelhard, M., Meusers, P., Reiser, M., Forstpointner, R., Metzner, B., Peter, N., Wörmann, B., Trümper, L., Pfreundschuh, M., Einsele, H., Hiddemann, W., Unterhalt, M. & Dreyling, M. (2009) Improvement of overall survival in advanced stage mantle cell lymphoma. Journal of Clinical Oncology, 27, 511518.
  • Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J.W. (2001) World Health Organization Classification of Tumours: Pathology and Genetics of Turnouts of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon.
  • Kahl, B.S., Li, H., Smith, M.R., Gascoyne, R.D., Paietta, E., Advani, R. & Horning, S.J. (2009) The VcR-CVAD regimen produces a high complete response rate in untreated mantle cell lymphoma (MCL): first analysis of E1405 – A phase II study of VcR-CVAD with maintenance rituximab for MCL. Blood (ASH Annual Meeting Abstracts), 114, 1661.
  • Katz, R.L., Caraway, N.P., Gu, J., Jiang, F., Pasco-Miller, L., Glassman, A.B., Luthra, R., Hayes, K.J., Romaguera, J.E., Cabanillas, F.F. & Medeiros, J. (2000) Detection of chromosome 11q13 breakpoints by interphase fluorescence in situ hybridization: a useful ancillary method for the diagnosis of mantle cell lymphoma. American Journal of Clinical Pathology, 114, 248257.
  • Leonard, J.P., Furman, R.R., Cheung, Y.K.K., Feldman, E., Cho, H.O., Vose, J.M., Nichols, G., Glynn, P.W., Joyce, M.A., Ketas, J., Ruan, J., Carew, J., Niesvizky, R., LaCasce, A., Chadburn, A., Cesarman, E. & Coleman, M. (2005) Phase I/II trial of bortezomib + CHOP-rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): phase I results. Blood (ASH Annual Meeting Abstracts), 106, 491.
  • Luthra, R., Sarris, A.H., Hai, S., Paladugu, A.V., Romaguera, J.E., Cabanillas, F.F. & Medeiros, L.J. (1999) Real-time 5 3 exonuclease-based PCR assay for detection of the (11; 14) (q13;q32). American Journal of Clinical Pathology, 112, 524530.
  • Martin, P., Chadburn, A., Christos, P., Weil, K., Furman, R., Ruan, J., Elstrom, R., Niesvizky, R., Ely, S., DiLiberto, M., Melnick, A., Knowles, D., Chen-Kiang, S., Coleman, M. & Leonard, J.P. (2009) Outcome of deferred initial therapy in mantle-cell lymphoma. Journal of Clinical Oncology, 27, 12091213.
  • Miyakoshi, S., Kami, M., Yuji, K., Matsumura, T., Takatoku, M., Sasaki, M., Narimatsu, H., Fujii, T., Kawabata, M., Taniguchi, S., Ozawa, K. & Oshimi, K. (2006) Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood, 107, 34923494.
  • O’Connor, O., Toner, L., Smith, E., Srinivasan, S., Hernandez, F., Rolf, M., Frankel, S. & Chanan-Khan, A. (2004) Combined targeting of the proteasome and Bcl-2 sensitizes human B-cell lymphoma and multiple myeloma to cyclophosphamide in vitro and in vivo models of these diseases. Blood (ASH Annual Meeting Abstracts), 104, 2484.
  • Ohri, A. & Arena, F.P. (2006) Severe pulmonary complications in African-American patient after bortezomib therapy. American Journal of Therapeutics, 13, 553555.
  • Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T. & Carbone, P.P. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology, 5, 649655.
  • Romaguera, J.E., Fayad, L., Rodriguez, M.A., Broglio, K.R., Hagemeister, F.B., Pro, B., McLaughlin, P., Younes, A., Samaniego, F., Goy, A., Sarris, A.H., Dang, N., Wang, M., Beasley, V., Medeiros, L.J., Katz, R.L., Gagneja, H., Samuels, B.I., Smith, T.L. & Cabanillas, F.F. (2005) High rate of durable remissions after retreatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. Journal of Clinical Oncology, 23, 70137023.
  • Romaguera, J.E., Fayad, L., Rodriguez, A., Hagemeister, F.B., Pro, B., McLaughlin, P., Younes, A., Samaniego, F., Shah, J., Weaver, P., Hartig, K., Cabanillas, F., Kwak, L., Kantarjian, H. & Wang, M. (2008) Rituximab (R) + HyperCVAD alternating with R-methotrexate/cytarabine after 9 Years: continued high rate of failure-free survival in untreated mantle cell lymphoma (MCL). Blood (ASH Annual Meeting Abstracts), 112, 833.
  • Smolewski, P., Duechler, M., Linke, A., Cebula, B., Grzybowska-Izydorczyk, O., Shehata, M. & Robak, T. (2006) Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells. Leukemia Research, 30, 521529.
  • Weigert, O., Pastore, A., Rieken, M., Lang, N., Hiddemann, W. & Dreyling, M. (2007) Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia, 21, 524528.
  • Weigert, O., Weidmann, E., Mueck, R., Bentz, M., Von Schilling, C., Rohrberg, R., Jentsch-Ullrich, K., Hiddemann, W. & Dreyling, M. (2009) A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation study. Leukemia & Lymphoma, 50, 716722.